Shockwave Medical Inc. (NASDAQ: SWAV) closed the day trading at $319.99 down -0.23% from the previous closing price of $320.72. In other words, the price has decreased by -$0.73 from its previous closing price. On the day, 623952 shares were traded.
Ratios:
For a better understanding of SWAV, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 72.33. For the most recent quarter (mrq), Quick Ratio is recorded 10.73 and its Current Ratio is at 11.76. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CL King on March 27, 2024, initiated with a Buy rating and assigned the stock a target price of $368.
On September 29, 2023, UBS started tracking the stock assigning a Neutral rating and target price of $218.
Morgan Stanley Upgraded its Equal-Weight to Overweight on July 10, 2023, whereas the target price for the stock was revised from $291 to $335.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 26 ’24 when Zacharias Isaac sold 4,000 shares for $287.67 per share. The transaction valued at 1,150,680 led to the insider holds 56,818 shares of the business.
FRANCIS LAURA sold 1,500 shares of SWAV for $450,000 on Mar 26 ’24. The Director now owns 3,551 shares after completing the transaction at $300.00 per share. On Mar 06 ’24, another insider, WATKINS FRANK T, who serves as the Director of the company, sold 2,000 shares for $253.65 each. As a result, the insider received 507,294 and left with 4,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SWAV now has a Market Capitalization of 11.97B and an Enterprise Value of 11.75B. As of this moment, Shockwave’s Price-to-Earnings (P/E) ratio for their current fiscal year is 82.88, and their Forward P/E ratio for the next fiscal year is 51.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 63.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.39 while its Price-to-Book (P/B) ratio in mrq is 17.70. Its current Enterprise Value per Revenue stands at 16.09 whereas that against EBITDA is 61.34.
Stock Price History:
Over the past 52 weeks, SWAV has reached a high of $331.58, while it has fallen to a 52-week low of $157.00. The 50-Day Moving Average of the stock is 260.09, while the 200-Day Moving Average is calculated to be 228.27.
Shares Statistics:
Over the past 3-months, SWAV traded about 596.02K shares per day on average, while over the past 10 days, SWAV traded about 1.02M shares per day. A total of 36.99M shares are outstanding, with a floating share count of 36.62M. Insiders hold about 2.07% of the company’s shares, while institutions hold 94.95% stake in the company. Shares short for SWAV as of Mar 15, 2024 were 1.79M with a Short Ratio of 3.00, compared to 1.92M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.78% and a Short% of Float of 6.23%.
Earnings Estimates
Current recommendations for the stock of the company come from 11 analysts. On average, analysts expect EPS of $0.97 for the current quarter, with a high estimate of $1.24 and a low estimate of $0.83, while EPS last year was $1.03. The consensus estimate for the next quarter is $1.2, with high estimates of $1.5 and low estimates of $1.07.
Analysts are recommending an EPS of between $6.18 and $3.99 for the fiscal current year, implying an average EPS of $4.84. EPS for the following year is $6.17, with 13 analysts recommending between $7.19 and $5.15.
Revenue Estimates
10 analysts predict $207.69M in revenue for the current quarter. It ranges from a high estimate of $210.1M to a low estimate of $205M. As of the current estimate, Shockwave Medical Inc.’s year-ago sales were $147.31M, an estimated increase of 41.00% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $226.67M, an increase of 25.80% less than the figure of $41.00% in the same quarter last year. There is a high estimate of $230.06M for the next quarter, whereas the lowest estimate is $223.73M.
A total of 13 analysts have provided revenue estimates for SWAV’s current fiscal year. The highest revenue estimate was $925.03M, while the lowest revenue estimate was $917.4M, resulting in an average revenue estimate of $920.88M. In the same quarter a year ago, actual revenue was $730.23M, up 26.10% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $1.13B in the next fiscal year. The high estimate is $1.17B and the low estimate is $1.08B. The average revenue growth estimate for next year is up 23.00% from the average revenue estimate for this year.
